Schizophrenia maintenance: a long-term safety and efficacy study in the treatment of schizophrenia

The primary objective of this 52-week study is to determine if flexible doses of an experimental medication are safe in the long-term treatment of schizophrenia. The secondary objective is to assess the maintenance of efficacy of the experimental drug in the treatment of schizophrenia.

• Are a man or woman between the ages of 18 and 75
• Agree to be hospitalized for 10 days
• Have a primary diagnosis of schizophrenia
• Have had no substance or alcohol abuse for six months prior to baseline
• Are in stable physical health

This is a partial list of eligibility requirements. To learn whether you are eligible for this study, call the phone number provided in the contact information section.